Group ergot dopamine agonists include the following substances: bromocriptine, cabergoline, dihydro

The European Medicines Agency (EMEA) has recommended the complete texts accompanying the active agents of the ergot dopamine agonists for new warnings and contraindications regarding the risk of fibrosis.
Group ergot dopamine agonists include the following substances: bromocriptine, cabergoline, dihydroergocryptine, lisuride and pergolide. These are used primarily in the treatment of Parkinson's disease.
For long-term use of ergot dopamine agonist is a known side effect of the development of fibrosis symptoms, especially cardiac. Evaluation of new scientific knowledge about the increased risk of fibrosis celgene in patients on chronic ergotaminovými derivatives suggests celgene that the development of fibrosis may occur much earlier than its symptoms are evident.
It is therefore recommended to supplement the texts accompanying the active agents of the ergot dopamine agonists for new warnings and contraindications regarding the risk of fibrosis. The risk for individual ergot derivatives differ:
Clinicians prescribing ergot dopamine agonists should take into account the new information, and during the treatment to monitor the possible development of fibrosis in both the heart and at another site. If patients have any questions regarding the treatment of ergotaminovými celgene dopamine agonist, it is advisable to consult a doctor or pharmacist.
Thank healthcare professionals celgene for the reporting celgene of suspected adverse drug reactions, which can be sent by post to the address celgene SIDC, Šrobárova celgene 48, Prague 10, 100 41, so e-mail to pharmacovigilance @ sukl com or fax to 272 185 816 It is also possible to use the electronic form for reporting adverse reactions, which is available on the website celgene SIDC.
Calendar of events << >> November 2013 Mon Tue Wed Thu Fri Sat 1 2 3 4 5 6 7 8 9 10 Distributors - report distributed supply medicinal products (Note SIDC) 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
lekarny.sukl.cz
Archive | Webmaster | Accessibility | Conditions of use of web presentation | Privacy Policy | Site visitors | Required Information | Contact Us | Site Map | Newsletter | RSS
Supplier portal QCM, sro